NuSkin Enterprises NUS APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition

APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition at other companies

XTI Aerospace, Inc.XTIA

$4.85M+965%

ADMA BiologicsADMA

$6.33M+36.9%

Schneider NationalSNDR

$200K-69.2%

CTO

Citius Oncology, Inc.CTOR

$3.53M+68.9%

Relmada Therapeutics, Inc.RLMD

$956.19K-73.2%

Monro, Inc.MNRO

$1.57M-22.5%

Revenue$320.6M-12.0%

Gross profit$214.5M-13.2%

Operating income$4.0M+141%

Net income$1.8M-98.3%

EPS (diluted)$0.04-98.1%

Cash & equivalents$198.7M-2.5%

Total debt$303.6M-8.2%

Total equity$794.1M+5.3%

Total assets$1.4B-1.1%

Operating cash flow-$3.9M-1,107%

CapEx$13.7M+1.0%

Free cash flow-$17.6M-33.6%

Market cap$256.35M-38.2%

Reported directly by NuSkin Enterprises in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.

The official record: NuSkin Enterprises’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is NuSkin Enterprises's APIC, share-based payment arrangement, option, increase for cost recognition?: NuSkin Enterprises (NUS) reported APIC, share-based payment arrangement, option, increase for cost recognition of -$4.16M in Q1 2026.
How has NuSkin Enterprises's APIC, share-based payment arrangement, option, increase for cost recognition changed year-over-year?: NuSkin Enterprises's APIC, share-based payment arrangement, option, increase for cost recognition decreased by 257.7% year-over-year, from -$1.16M to -$4.16M.